Page 22 - EFH223

El Farmacéutico Hospitales. 2022; 223: 13-22
34. Trinkley KE, Page RL 2nd, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Curr Med Res Opin. 2013; 29(12): 1.719-1.726
[DOI: 10.1185/03007995.2013.840568. PMID: 24020938].
35. Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J, et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J. 2014; 35(20): 1.306-1.315 [DOI: 10.1093/eurheartj/ehu100. PMID: 24644307].
36. Beitland S, Platou ES, Sunde K. Drug-induced long QT syndrome and fatal arrhythmias in the intensive care unit. Acta Anaesthesiol Scand. 2014; 58(3): 266-272 [DOI: 10.1111/ aas.12257] [PMID: 24397608].
37. Tisdale JE. What causes some patients with drug-induced QT interval prolongation to develop torsades de pointes but not others? The elusive missing link. Drugs Aging. 2014; 31(8): 577-579 [DOI: 10.1007/s40266-014-0199-8] [PMID: 25023065].
38. Khan Q, Ismail M, Haider I, Ali Z. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients. J Formos Med Assoc. 2019; 118(1 Pt 1): 109-115 [DOI: 10.1016/j.jfma.2018.01.016] [Epub 2018 Feb 17. PMID: 29458991].
39. Paulos CP, Nygren CE, Celedon C, Carcamo CA. Impact of
a pharmaceutical care program in a community pharmacy
on patients with dyslipidemia. Ann Pharmacother. 2005; 39(5): 939-943.
40. Kane SL, Weber RJ, Dasta JF. The impact of critical care pharmacists on enhancing patient outcomes. Intensive Care Med. 2003; 29(5): 691-698.
41. Leape LL, Cullen DJ, Clapp MD, Burdick E, Demonaco HJ, Erickson JI, et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282: 267-270.
42. Scarsi KK, Fotis MA, Noskin GA. Pharmacist participation
in medical rounds reduces medication errors. Am J Health Syst Pharm. 2002; 59(21): 2.089-2.092.
43. Gandhi PJ, Smith BS, Tataronis GR, Maas B. Impact of a pharmacist on drug costs in a coronary care unit. Am J Health Syst Pharm. 2001; 58(6): 497-503.
44. Guignard AP, Couray-Targe S, Colin C, Chamba G. Economic impact of pharmacists’ interventions with nonsteroidal antiinflammatory drugs. Ann Pharmacother. 2003; 37(3): 332-338.
22
el farmacéutico hospitales n.o 223